Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$318,846Cash on Hand
0.8mo Cash Runway
6.5%Short Interest
Follow XRTX by emailGet an email when XRTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about XRTX, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
XORTX completed manufacturing and packaging of clinical drug supply for the XRX-OXY-102 trial of XORLO, its oxypurinol tablet for gout. The company is preparing a Clinical Trial Application for Health Canada alongside a planned FDA IND filing. Form 6-K · SEC filing · Press release
Nov 16, 2026 ·
Earnings Reported unaudited nine-month results to September 30, 2026: net loss of $2,881,306 versus $2,065,842 a year earlier, with cash of $318,846 at quarter end. Shares were consolidated 5:1 on April 6, 2026, and the company voluntarily delisted from the TSX Venture Exchange effective September 1, 2026. Form 6-K · SEC filing · Press release
Nov 13, 2026 ·
Regulatory XORTX said the Japan Patent Office issued a Decision to Grant for Japanese Patent Application No. 2022-556140 covering xanthine oxidase inhibitor compositions for acute kidney injury tied to viral infection. Once registered, the patent is expected to last until March 15, 2041. Form 6-K · SEC filing · Press release
Oct 8, 2026 ·
Regulatory XORTX outlined a planned Health Canada Clinical Trial Application for XRx-026, its oxypurinol gout program (XORLO), to run part one of the XRX-OXY-102 study in Canada and support its planned FDA NDA filing. No agreement with any commercialization partner has been entered. Form 6-K · SEC filing · Press release
Sep 18, 2026 ·
Regulatory Plans to submit an IND to the FDA for its XRx-026 gout program, using its XORLO oxypurinol formulation, in the fourth quarter of 2026. A two-part XRX-OXY-102 trial would come before an NDA, targeted in about one year and subject to funding. The company estimates a US$700M annual market opportunity. Form 6-K · SEC filing · Press release
Sep 10, 2026 ·
XORTX began contract manufacturing of GMP oxypurinol drug substance and clinical supply tablets for XORLO, supporting the planned XRX-OXY-102 clinical study and future FDA marketing approval. The company expects validation and stability data to support its NDA filing. Form 6-K · SEC filing · Press release
Sep 9, 2026 ·
Deal XORTX re-engaged IR Agency LLC for investor relations and marketing services following its voluntary delisting from the TSX Venture Exchange, on substantially the same terms as previously disclosed in May and August 2026. Form 6-K · SEC filing · Press release
Sep 4, 2026 ·
Deal XORTX ended its IR agency deal in August and got back the $2,500,000 it had paid. A new three-month agreement with IR Agency starts September 3, 2026, for up to 10 news distribution campaigns, with a $2,500,000 fee paid in advance that is non-refundable. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
XRTX holds $318,846 in cash and short-term investments and burns about $1.3M/quarter from operations,
an estimated runway of 0.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:45 · Elevated
Cash runway 1 months +40
ATM program on file since Dec 2024 +15
Raised after last reported balance sheet (May 2026) -10
Recent financing filings on SEC EDGAR:
May 15, 2026 · Registered direct / best-efforts offering · 424B4
Oct 23, 2025 · Registered direct / best-efforts offering · 424B5
Insiders Form 4 data not loaded yetInstitutions (4 holders) 0.9%Public and other holders 99.1%
Holder
Type
Shares
% of shares
As of
Stonex Group Inc.
Institution (13F)
15,973
0.12%
2026-09-30
Clearstead Advisors, LLC
Institution (13F)
55
0.00%
2026-09-30
TD Waterhouse Canada Inc.
Institution (13F)
9
0.00%
2026-09-30
Share count 12,989,678 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full XRTX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for XRTX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.